After demerger of pharma business, up to 37% upside seen in Piramal Enterprises | Economic Times

After demerger of pharma business, up to 37% upside seen in Piramal Enterprises https://ift.tt/6Jfiy3z management will now be looking to scale up its loan book, which will entail a consolidation in the wholesale book and strong growth in retail. Even the retail mix will improve, which may translate into a decline in borrowing costs and an upgrade in its credit rating, said Motilal Oswal.